Coronavirus company news summary – Gilead looking to scale up remdesivir manufacturing – India produces guidelines on off-label use of HIV drugs for Covid-19

Allie Nawrat 7 May 2020 (Last Updated May 7th, 2020 08:47)

7 May 2020

The Council of Scientific and Industrial Research (CSIR) in India has proposed the testing of sepsis treatment drug as a vaccine for Covid-19. CSIR is currently repurposing a mycobacterium w drug for gram-negative sepsis as part of randomised clinical trials to treat severely ill Covid-19 patients. The trials are currently being conducted by CSIR in partnership with Cadila Pharmaceuticals.

Gilead Sciences is in discussion with some leading pharmaceutical manufacturing firms to support the manufacture of its patented antiviral drug remdesivir. This drug received emergency use authorisation from the US Food & Drug Administration recently to Covid-19 patients.

LakePharma has announced that the company will be supplying the Mount Sinai Health System recombinant SARS-CoV-2 spike proteins to the Mount Sinai Laboratory to make up part of its blood test for antibody response against SARS-CoV-2, the virus that causes Covid-19.

India’s apex body Indian Council for Medical Research has given detailed guidelines on the use of Lopinavir/ritonavir, a HIV fixed dose drug combination, which is being repurposed for Covid-19. As per the guidelines, this drug can be used on patients in hospitals suffering with a moderate degree of severity.